DS 7411
Alternative Names: DS-7411Latest Information Update: 28 Feb 2022
At a glance
- Originator Daiichi Sankyo Company
- Class Antibodies; Antihaemorrhagics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Haemophilia A; Haemophilia B
Highest Development Phases
- No development reported Haemophilia A; Haemophilia B
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Haemophilia-A in Japan
- 28 Feb 2022 No recent reports of development identified for preclinical development in Haemophilia-B in Japan
- 18 Apr 2018 DS 7411 is available for licensing as of 31 Jan 2018. http://www.irwebcasting.com/20180131/5/02cbd6521f/media/20180131_daiichisankyo_en_dl_01.pdf